Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Operating Leases came in at $31.1 million in Q1 2026, down 5.51% YoY from $32.9 million in Q1 2025, and down 1.5% on a QoQ basis from $31.5 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Operating Leases (2022 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 5 years of Operating Leases data on file, last reported at $31.1 million in Q1 2026.
- Quarterly Operating Leases fell 5.51% year-over-year to $31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.1 million (down 5.51% YoY) and the FY2025 annual result came in at $31.5 million, down 5.2% from the prior year.
- Operating Leases fell to $31.1 million in Q1 2026, from $31.5 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $38.6 million in Q2 2025 to a low of $9.3 million in Q1 2023.
- A 5-year average of $30.8 million and a median of $33.8 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases surged 269.75% — and 2026, when it decreased 5.51%.
- Tracing XERS's Operating Leases over 5 years: stood at $9.4 million in 2022, then surged by 269.75% to $34.8 million in 2023, then declined by 4.33% to $33.3 million in 2024, then slipped by 5.2% to $31.5 million in 2025, then fell by 1.5% to $31.1 million in 2026.
- The last three Operating Leases figures came in at $31.1 million (Q1 2026), $31.5 million (Q4 2025), and $38.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.48 Bn | 1.36 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.85 Mn |
| Mar 31, 2026 | 31.06 Mn |
| Dec 31, 2025 | 31.53 Mn |
| Sep 30, 2025 | 38.19 Mn |
| Jun 30, 2025 | 38.60 Mn |
| Mar 31, 2025 | 32.87 Mn |
| Dec 31, 2024 | 33.26 Mn |
| Sep 30, 2024 | 33.64 Mn |
| Jun 30, 2024 | 34.02 Mn |
| Mar 31, 2024 | 34.40 Mn |
| Dec 31, 2023 | 34.76 Mn |
| Sep 30, 2023 | 35.15 Mn |
| Jun 30, 2023 | 34.87 Mn |
| Mar 31, 2023 | 9.35 Mn |
| Dec 31, 2022 | 9.40 Mn |